Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II Trial of JL15003 Injection in Recurrent Glioblastoma
ChiCTR2600119764Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of JL15003 in glioblastoma (GBM) (3 arms), sponsored by Huashan Hospital. Primary endpoints: Incidence and severity of adverse events (AEs), Clinical laboratory test results and 3 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JL15003
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600119764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119764.